









CJC-1295 without DAC has a short duration of action, which allows natural GH pulses. Suitable for more flexible protocols when support for growth hormone and recovery is sought. Often combined with Ipamorelin for a better anabolic response.
- 0%
- 0%
- 0%
- 0%
- 0%
Reviews Over CJC-1295 without DAC
Total Reviews (0)
click here write review to add review for this product.
Report this review.
What is CJC-1295 without DAC?
This peptide gives the body a "signal" to release more of its own growth hormone in pulses, which can change how tissues are repaired and how energy is used, without the peptide itself replacing the hormone directly.
The agonism of the GHRH receptor (GPCR) in the pituitary is the central signaling pathway behind the profile of CJC‑1295 without DAC: it is a synthetic analogue of growth hormone–releasing hormone (GHRH), designed to enhance the pulsatile secretion of GH and the subsequent increase in IGF‑1. The molecule is "without DAC", i.e., without a drug‑affinity complex modification, which is relevant for experimental design with short‑acting GHRH mimetics (exposure control and temporal profiling). Reference information: Wikipedia: CJC‑1295.
Mechanism of action
After receptor activation an increase in cAMP/PKA signaling in somatotrophs and amplification of GH pulses is expected; downstream there is an increase in circulating IGF‑1 as a functional biomarker. For context on the GH/IGF‑1 axis and GHRH biology: NCBI Bookshelf (endocrinology, GH axis); for regulatory context of IGF‑1 as a marker/risk considerations during GH modulation: FDA (general regulatory resources).
Reliable, standardized numerical results are lacking in open sources; the available descriptions are fragmentary and do not allow correct quantitative interpretation.
Scientific use in a laboratory setting
In laboratory settings it is used to study the GH axis (GH/IGF‑1), receptor pharmacology of GHRH‑R, temporal profiles of secretory pulses and in vitro models (cell lines/primary cultures). Not intended for clinical use; when working with it validated analytical methods (HPLC/LC‑MS) and control of matrix/adsorption in plastics are recommended.
Pharmacokinetics
Due to the absence of DAC, a shorter functional window of action is expected compared with long‑acting modifications; this makes dosing frequency in the protocol, sample timing and the kinetics of biomarkers (serum GH and IGF‑1) important.
Purity and specification
CJC‑1295 without DAC from MyPeptid provides a reliable basis for analytical verification and in vitro/in vivo studies with purity above 99%.
Formula: C152H252N44O42
Sold only for educational and research purposes (research‑only), to laboratories and scientific professionals.